Development of leading first-generation vaccines against SARS-CoV-2.
SARS-CoV-2 has infected more than 152 million individuals globally. Highly effective and safe vaccines are required to accelerate the development of herd immunity to end the pandemic. This review focuses on vaccines that are being developed at unprecedented speed globally and are completing late phase clinical trials to meet this urgent need.
Authors: Pin-Yu Perera, Liyanage P Perera